The CONCERT-HF trial revealed cell-type-specific therapeutic effects: MSCs primarily improved patient-reported quality of life, whereas c-kit-positive cardiac progenitor cells (CPCs) demonstrated superiority in reducing major adverse cardiovascular events—a difference whose mechanism remains to be elucidated (227). This evidence concerns the gene KIT and hydrops fetalis.